Built on the company’s now-patented innovations, Ategenos SmartPatches contain reformulated oral solid dose (OSD) blockbuster drugs in a connected, transdermal SmartPatch that delivers sustained-release therapy over multiple days, while also detecting missed doses and automatically alerting caregivers to make interventions.

This marks the first time a drug delivery system has combined passive drug administration with active, cloud-connected intelligence, aiming to reduce the estimated $528.4 billion in U.S. healthcare costs ($1T globally) driven by medication non-adherence.

“We’re building a new layer of intelligence into the fabric of pharmacotherapy,” said Don DeGolyer, CEO of Ategenos. “When medications go untaken, it’s not just dollars lost. It’s people’s lives unravelling through preventable relapses, hospital stays, and declining independence. Our SmartPatches enable early interventions, giving patients a better chance to stay well, at home, and in control of their lives.”